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Abstract Recent results suggest an activation of T-lymphocytes 
via the CD40L implying a dual function of this ligand involved in 
the activation of both B- and T-lymphocytes [1-4]. Here, we 
provide evidence that activation of T-lymphocytes via CD40L 
results in activation of a neutral but not an acidic sphingomye- 
linase correlating with a consumption of sphingomyelin and a 
release of ceramide. Activation of the neutral sphingomyelinase 
by the CD40L seems to involve a novel signalling cascade since it 
is independent of CD40L induced protein kinase activation or 
association of the neutral sphingomyelinase with the CD40L. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The interaction of the CD40 receptor on B cells with the 
CD40-1igand (CD40L, gp39 or TRAP) on T-lymphocytes has 
been shown to be crucial for proliferation, differentiation, 
isotype switching and survival of B-lymphocytes in germinal 
centers [5,6]. Disruption of the physiological interaction of the 
CD40L with its receptor, e.g. by mutations of the CD40L or 
in experimental knock-out models, results in the development 
of immunodeficiencies, in particular the X-linked hyper-IgM 
syndrome [1,7-14]. This syndrome is characterized by an im- 
munodeficiency with normal or elevated IgM levels and inef- 
ficient synthesis of IgG or IgA due to impaired B-cell stimu- 
lation [7-11]. The CD40L has been shown to be expressed on 
T-lymphocytes, mast cell, basophils, NK  cells, monocytes and 
even in B lymphocytes [15 19]. The CD40L is a 39 kDa type 
II membrane glycoprotein with a 22 amino-acid cytoplasmic 
amino terminal tail. The cytoplasmic domains of mouse and 
human CD40L are 82% identical [6] implying and important 
role of the cytoplasmic domain in CD40L function, however, 
the domain lacks any known enzymatic activity [6]. In fact, 
some data indicate that binding of the CD40L to the CD40- 
receptor may not only result in B cell activation but also in 
stimulation of T-lymphocytes [14]. 
In the present study we provide evidence for a novel signal- 
ling pathway coupled to the CD40L. Triggering T-lympho- 
cytes via the CD40L results in a protein kinase independent 
activation of the neutral sphingomyelinase. Activation of the 
neutral sphingomyelinase correlates with a CD40L induced 
consumption of sphingomyelin and release of ceramide which 
are also not affected by protein kinase inhibitors. 
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2. Methods 
2.1. Cell culture and stimulation 
All reagents were purchased from Sigma, if not otherwise cited. 
Murine CD40L positive or negative EL4 T-lymphocytes [20] were 
grown in RPMI-1640 medium supplemented with 10% fetal calf se- 
rum, 10 mM HEPES (pH 7.4), 2 mM u-glutamine, 100 ~tM non 
essential amino acids, 1 mM sodium pyruvate, 100 U/ml penicillin, 
100 ~tg/ml streptomycin (all from Life Technologies, Eggenstein, Ger- 
many) and 50 ~tM 13-mercaptoethanol. 
Herbimycin A (Calbiochem, Bad-Soden, Germany), a specific in- 
hibitor of src-like tyrosine kinases, or staurosporine, a broad kinase 
inhibitor, were added to the ceils 12 h or 5 min, respectively, prior to 
any assay at a concentration of 10/,tM for herbimycin A or 1 ~tM for 
staurosporin. For activation, cells were washed twice in sterile 
HEPES/saline (H/S, 132 mM NaCI, 20 mM HEPES, 5 mM KCI, 
1 mM CaCI2, 0.7 mM MgC12, 0.8 mM MgSO4) and stimulated at 
37°C with 2 Ixg/ml monoclonal anti-mouse CD40L-antibody (Phar- 
mingen, San Diego, CA, USA). 
2.2. Sphingomyelin consumption 
Cells (5.106/sample) were metabolically abelled by incubation with 
1 ~tCi/ml [methyl-3H]choline chloride (60-90 Ci/mmol; NEN-DuPont, 
Bad-Homburg, Germany) for 48 h in complete RPMI. Cells were 
washed in H/S and stimulated via the CD40L using 2 lag/ml mono- 
clonal anti-mouse CD40L-antibody. Lipids were extracted by addi- 
tion of 120 111 0.22 M HC1, 2.7 ml CHC13:CH3OH (2:1), 0.9 ml of 
CHCI3 and 0.9 ml of 1 M KC1. The organic phase was collect- 
ed, dried, resuspended in CHCI3:CH3OH (1:1) and lipids were 
separated on G60 silica gel thin layer chromatography plates (Mach- 
ery-Nagel, Dueren, Germany) using CHCI3:CH3OH:H20:acetic 
acid (50:30:8:4) as solvent system. Sphingomyelin spots were iden- 
tified in I2-vapor by co-migration with standards, scrapped from the 
plate and radioactivity was determined by liquid scintillation count- 
ing. 
2.3. Activity of acidic and neutral sphingomyelinase 
For acidic sphingomyelinase ctivity measurements cells (10V/sam - 
pie) were stimulated with anti-CD40L, lysed in ice-cold 50 mM Tris 
(pH 7.4), 10 mM bacitracin, 1mM benzamidine, 10 mM Na3VO4, 10 
~tg/ml each aprotinin and leupeptin, 0.1 mg/ml soybean trypsin inhib- 
itor and 0.2% Triton X-100 and immediately sonicated for 10 s. Son- 
ication was repeated three times and insoluble cell debris was pelleted 
by 5 min centrifugation at 600×g. An equal amount of 50 mM Tris 
(pH 7.4), 3% NP40, 1% Triton X-100, 10 mM Na3VO4, 100 ~tg/ml 
each aprotinin and leupeptin ('ASM lysis buffer') was added to the 
samples and ASM was immunoprecipitated from the supernatants 
using a goat-anti-ASM-antiserum previously characterised [21]. Sam- 
ples were incubated for 4 h at 4°C, immunocomplexes were immo- 
bilized by addition of 20 ~tl protein A/G coupled agarose (Santa Cruz 
Inc., Santa Cruz, CA) and further incubation for 60 min at 4°C. The 
immunoprecipitates were washed three times in lysis buffer followed 
by additional three washes in 50 mM sodium acetate (pH 5.0), 0.2% 
Triton X-100, 1 mM Na3VO4 and 10 ~tg/ml each aprotinin and leu- 
peptin. Washed immunoprecipitates were incubated with [14C] sphin- 
gomyelin (0.5/aCi/sample, 54.5 mCi/mmol; NEN-DuPont) in 250 mM 
sodium acetate (pH 5.0), 1.3 mM EDTA, 0.05% NP40 (assay buffer) 
for 30 min at 37°C. The substrate [14C]sphingomyelin was dried and 
solubilized by 10 rain bath sonication in assay buffer. Samples were 
then extracted with chloroform : methanol (2 : 1) and H20, the 
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upper phase was collected and radioactivity reflecting the degradation 
of [laC]sphingomyelin was determined by liquid scintillation counting. 
The activity of the ASM in whole cell lysates was determined by 
lysis of the cells in a buffer consisting of 0.1% Triton X-100, 50 mM 
sodiumacetate, 1 mM Na3VO4 and 10 ~g/ml each aprotinin and leu- 
peptin. Extracts were sonicated centrifuged at 600 × g for 5 min and 
the supernatants were added to the same volume of 0.5 ~Ci/sample 
[14C]sphingomyelin i  250 mM sodiumacetate (pH 5.0, 1.3 mM 
EDTA and 0.05% NP-40. [14C]sphingomyelin was prepared as de- 
scribed above. Samples were incubated, extracted and counted as 
described for the immunoprecipitates. 
For determination f neutral sphingomyelinase activity, cells were 
lysed in a buffer consisting of 20 mM HEPES (pH 7.4), 5 mM Di- 
thiothreitol, 2 mM EDTA, 10 mM MgCI2, 0.1 mM Na2MoOl, 10 
mM [$-glycerophosphate, 7.5 laM ATP, 1 ~M PMSF, 10 ~tM leupeptin 
and 0.2% Triton-Xl00. Extracts were processed as above with 0.5 
~tCi/sample [l~C]sphingomyelin as substrate. The substrate was solu- 
bilized by bath sonication for 10 min in a buffer consisting of 20 mM 
HEPES (pH 7.4), 1 mM MgCI~ and 0.2% Triton X-100 and 75 p.l of 
the substrate were added to 100 ~tl lysates. 
2.4. Co-immunoprecipitation of eutral sphingomyelinase 
Cell (2.107/sample) stimulation was terminated by lysis in 50 mM 
Tris (pH 7.4), 10 mM Bacitracin, 1 mM benzamidine, 10 mM 
Na3VO4, 10 ~tg/ml each aprotinin and leupeptin, 0.1 mg/ml soybean 
trypsin inhibitor and 0.2% Triton X-100 (buffer A) or, alternatively, in 
25 mM HEPES (pH 7.4), 2% NP40, 1% Triton X-100, 125 mM NaC1, 
10 mM each NaF, Na3VO4 and sodium pyrophosphate and 10 ~g/ml 
of each aprotinin and leupeptin (buffer B). After three rounds of 
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sonication for 10 s each, DNA and cell debris were pelleted by cen- 
trifugation at 20000×g for 15 min and the supernatants were sub- 
jected to immunoprecipitation overnight at 4°C using 3 ~tg anti- 
DC40L antibodies/sample (Pharmingen, San Diego, CA). After addi- 
tion of protein A/G-coupled agarose (Santa Cruz Inc.) incubation was 
continued for at least 60 min. Immunocomplexes were washed twice 
times in lysis buffer, three times in 20 mM HEPES (pH 7.4), 1 mM 
MgCI2 and 0.2% Triton X-100 with 0.05 mCi/sample [11C]- 
sphingomyelin and finally extracted as above. Degradation of 
[]4C]sphingomyelin reflecting the activity of any co-immunoprecipi- 
tared neutral sphingomyelinase w  determined by liquid scintillation 
counting. Control immunoprecipitates w re performed with an irrele- 
vant monoclonal mouse Immunoglobulins. 
2.5. Determination of ceramide 
For determination f ceramide, cells were stimulated as above for 
the indicated times and the lipids were extracted with 
CHCI3 :CH3OH:HCI (100:100:1). The organic phase was dried under 
vacuum, diacylglycerol was digested by mild alkaline hydrolysis in 0.1 
M methanolic KCI, the samples were reextracted asabove, dried and 
solubilized by 10 min bath sonication in 7.5% (w/v) n-octyl-13-gluco- 
pyranoside, 5 mM cardiolipin, 1 mM diethylenetTiamine-pentaacetic 
acid (DETAPAC). After sonication 40 ~tg/ml of purified E. coli DAG- 
kinase (Amersham, Braunschweig, Germany) in 70 ~tl reaction buffer 
(100 mM imidazole-HCl (pH 6.6), 100 mM NaC1, 25 mM MgC12 and 
2 mM EGTA) supplemented with 10 ~tCi/sample [:~P]TATP and 1 mM 
ATP were added and the samples were incnbated at 22°C for 30 min. 
Kinase reaction was stopped by addition of 1 ml CHC13 :CH:~OH :HCI 
(100:100:1), 170 #1 of salt solution (10 mM HEPES (pH 7.2), 135 mM 
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Fig. I. Stimulation of T-lymphocytes via the CD40L results in activation of the neutral sphingomyelinase (A) but not the acidic sphingomyeli- 
nase (B). Activation of the neutral sphingomyelinase correlates wi h a consumption of sphingomyelin and a release of ceramide upon CD40L 
triggering (C). Cells were stimulated via the CD40L for the indicated time, lysed and activity of the neutral or acidic sphingomyelinase was de- 
termined in the lysates by degradation of the substrate [laC]sphingomyelin. Consumption of sphingomyelin or release of ceramide was measured 
by organic extraction of stimulated or unstimulated ceils and separation of lipids by TLC for sphingomyelin or incubation of the extracts with 
a ceramide sensitive kinase and [32P]TATP followed by TLC-separation and autoradiography for ceramide. Panel C shows the change of sphin- 
gomyelin and ceramide in pmol]106 cells. Panel D displays a representative autoradiography from a TLC-plate obtained after incubation of the 
extracts with ceramide sensitive kinase. Experiments were repeated at least three times with similar results. 
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NaCI, 1.5 mM CaC12, 0.5 mM MgC12 and 5.6 mM glucose) and30 ~tl 
of 100 mM EDTA. The lower organic phase was dried, resuspended 
in CHCI3 :CH3OH (1:1) and resolved by TLC using CHCI3 :CHzOH: 
acetic acid (65:15:5, v/v/v) as solvent. Spots were visualized by auto- 
radiography, scraped from the plate and nalyzed by liquid scintilla- 
tion counting. 
The ceramide content of the samples was determined by compar- 
ison with a standard curve comprised of known quantities of DAG or 
ceramide. 
3. Results 
We have recently demonstrated the activation of two dis- 
tinct signalling pathways upon cellular stimulation via the 
CD40-1igand. First, CD40L triggering results in an activation 
of a pathway from src-like tyrosine kinases, which seem to 
couple the CD40L to Rac 1 and JNK/p38-K (B. Brenner et 
al., submitted for publication). Second, CD40L triggering in- 
duces a herbimycin A sensitive activation of PLC 7, the release 
of IP3 and Ca 2+ and finally the activation of PKC. In order to 
identify novel signalling pathways involved in cellular activa- 
tion via the CD40L, we tested whether stimulation of CD40L 
positive mouse EL-4 T-cells with a monoclonal anti-CD40L 
antibody results in an alteration of lipid metabolism. The 
results (Fig. 1A) show an approximately 1.8-fold activation 
of the neutral sphingomyelinase activity whereas no stimula- 
tion of the acidic sphingomyelinase could be detected (Fig. 
1B). Stimulation of Jurkat cells via the CD95 receptor resulted 
in an approximately 2-fold stimulation of the acidic sphingo- 
myelinase (Fig. 1 B) showing that the acidic sphingomyelinase 
can be activated in these cells under the present assay condi- 
tions. Fig. 1B displays the results detecting the ASM activity 
in cell lysates, similar results were obtained by measuring the 
activity of immuoprecipitated ASM. The activity of the neu- 
tral sphingomyelinase was observed as early as 10 min and 
remained increased for more than 40 rain. The activation of 
the neutral sphingomyelinase correlated with a consumption 
of cellular sphingomyelin and a release of ceramide (Fig. I C 
and D). 
The neutral sphingomyelinase has been only biochemically 
characterised and the gene is not cloned. Furthermore almost 
nothing is known about the mechanism of neutral sphingo- 
myelinase activation in the cell. A recent study demonstrated 
that the FAN-protein [22] plays an important role in neutral 
sphingomyelinase regulation, h wever, no further or direct 
signalling events have been identified. To gain some insight 
into the mechanism of neutral sphingomyelinase ctivation by 
the CD40L, we tested the involvement of protein kinases. 
Cellular activation via CD40L has been previously shown to 
result in a rapid stimulation of p561ck (B. Brenner et al., 
submitted for publication). Thus, src-like tyrosine kinases 
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are possible candidates for an upstream regulator of the neu- 
tral sphingomyelinase upon CD40L triggering. However, the 
activation of the neutral sphingomyelinase was not affected by 
preincubation of the cells with the broad kinase inhibitor 
staurosporine or the src-like tyrosine kinase specific inhibitor 
herbimycin A (Fig. 2A) indicating that the neutral sphongo- 
myelinase is not regulated via a protein tyrosine kinase upon 
CD40L mediated cell stimulation. This notion is supported by 
our failure to show any neutral sphingomyelinase activity in 
immunoprecipitates performed with the monoclonal anti- 
phosphotyrosine antibody 4G10 (Fig. 2B). The lack of neutral 
sphingomyelinase inhibition after preincubation with stauro- 
sporine or herbimycin A correlated with a failure of the in- 
hibitors to change the consumption of sphingomyelin or the 
release of ceramide after treatment with anti-CD40L antibod- 
ies (Fig. 2C). 
To further elucidate the mechanism of neutral sphingomye- 
linase activation we tested the activity of the neutral sphingo- 
myelinase in immunoprecipitates of the CD40L. Association 
of proteins i a very common motif involved in the activation 
or targeted localization of distinct proteins involved in cellular 
signalling. Furthermore, the FAN protein which seems to 
couple some receptors with the neutral sphingomyelinase 
has been shown to associate with the TNF-receptor. If the 
CD40L associate with the neutral sphingomyelinase prior or 
after cellular stimulation, CD40L immunoprecipitates should 
contain a sphingomyelinase activity. However, no associated 
sphingomyelinase could be detected in CD40L immunopreci- 
pitates obtained from either unstimulated or stimulated EL-4 
cells (Table 1). The same results were obtained using two 
different buffers resembling very mild (buffer A) or stronger 
(buffer B) lysis conditions. These data suggest hat two pro- 
teins do not associate. 
4. Discussion 
Our data provide evidence for a novel function of the 
CD40L, i.e. the activation of the neutral sphingomyelinase 
in T-lymphocytes. In this concept, the CD40L behaves as a 
bifunctional molecule, first as the ligand for the CD40-recep- 
tor and simultaneously as receptor molecule activating T-lym- 
phocytes. Previous data from our laboratory showed a rapid 
activation of the Src-like tyrosine kinase p561ck upon trigger- 
ing the CD40L. These studies demonstrated that cellular acti- 
vation via CD40L also result in a stimulation of PLCT, a 
release of Ca 2+ and IP3, an activation of PKC and, on the 
other hand, a stimulation of Rac 1 as well as of JNK/p38-K. 
The activation of these two signalling pathways eems to de- 
pend on the function of the src-like tyrosine kinases p561ck 
since inhibition with herbimycin A prevented the stimulation 
Table 1 
The neutral sphingomyelinase doe  not associate with the CD40L prior or after cellular stimulation via the CD40L 
Time of stimulation Whole cell lysates CD40L-Ipt. buffer A CD40L-Ipt. buffer B 
(% activity) 
0 min 100 + 9 1.9 + 0.4 1.5 + 0.3 
30 min 180+ 11 2.1 +0.7 1.7+0.5 
Cells were stimulated via the CD40L for 30 min, lysed in buffer A or B as described above andthe CD40L was immunoprecipitated using an anti- 
CD40L antibody. Neither the immunoprecipitates prepared under ve y mild lysis conditions (buffer A) nor with stronger lysis conditions (buffer B) 
contained any neutral sphingomyelinase activity indicating that he two proteins do not associate. Control lysates (using buffer A) obtained from an 
aliquot of the same cells showed significant neutral sphingmyelinase activity. CD40L immunoprecipitates were also prepared 5, 10, 20 or 40 min 
after stimulation via the CD40L and did not show any associated neutral sphingomyelinase activity. 
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Fig. 2. Activation of the neutral sphingomyelinase (A nd B), con- 
sumption of sphingomyelin (C) or release of ceramide (D). after 
CD40L triggering is not regulated by protein kinases. Preincubation 
of EL4 cells with 1 /aM staurosporine or 10 pM herbimycin A does 
not alter the activation of neutral sphingomyelinase after stimulation 
via the CD40L (A). Likewise, immunoprecipitates performed with 
the monoclonal anti-phosphotyrosine antibody 4GI0 id not con- 
tain any neutral sphingomyelinase is not directly phosphorylated 
(B). Finally, the consumption of cellular sphingomyelin or the re- 
lease of ceramide are not altered after preincubation of the cells 
with staurosporine of herbimycin A (C). 
of PLCT/PKC as well as of Rac 1 and JNK/p38-K. However, 
the activation of the neutral sphingomyelinase seems to be 
completely independent of tyrosine or serine/threonine kinase 
activity since pretreatment with the broad kinase inhibitor 
staurosporine or the Src-like tyrosine kinase blocker herbimy- 
cin A did not affect the stimulation of the neutral sphingo- 
myelinase by CD40L. 
A recent study suggested a regulation of the neutral sphin- 
gomyelinase via the FAN-protein, which associates with the 
TNF-receptor [22]. However, co-immunoprecipitation experi- 
ments with anti-CD40L did not detect any neutral sphingo- 
myelinase associated with the CD40L suggesting that, at least 
under the present conditions, the two proteins do not form a 
complex prior or after cellular stimulation via the CD40L. 
Since the antibody binds to the extracellular domain of the 
CD40L, it seems to be unlikely that the lack of neutral sphin- 
gomyelinase in the precipitates i  due to a steric inhibition of 
the immunoprecipitation antibody with the associated neutral 
sphingomyelinase. However, since no antibodies to the neutral 
sphingomyelinase ar  available a positive control for the im- 
munoprecipitates can not be included, thus, we can not com- 
pletely exclude that our failure to show an association of the 
neutral sphingomyelinase with the CD40L is due to a trivial 
technical reason. 
FAN associates with the TNF-receptor via a domain con- 
sisting of a specific motif (QKWEDSAHK) [22]. This domain 
is lacking in the CD40L (the CD40L contains a domain with 
weak homology (QxxxxSAxx), thus, it might be possible that 
the CD40L activates the neutral sphingomyelinase viaa com- 
pletely novel signalling mechanism. 
Our results suggested a novel function of the CD40L, i.e. 
the ligand may also function as a receptor. The new concept is 
supported by previous findings. First, the best evidence for a 
stimulatory function of the CD40L for T-lymphocytes is pro- 
vided by CD40-receptor knock-out mice [l]. These mice lack 
germinal centers, however, the formation of germinal centers 
upon injection of the antigen DNP-KLH can be initiated by 
co-injection of soluble CD40L-Fc molecules implying that 
cellular stimulation via the CD40L has a crucial function in 
the initiation of germinal center formation. These data suggest 
that the interaction of the CD40-receptor with the CD40L 
results in a stimulation of the T-lymphocytes and is required 
for normal T-cell function. Second, highly purified peripheral 
T-cells responded to anti-CD40L and anti-TCR/CD3 plus 
anti-CD28 triggering with a much higher I L-4 synthesis than 
observed after stimulation without involvement of the CD40L 
[2]. Likewise, co-incubation of CD40-receptor transfected 
P815 cells with human small, CD4 ~, CD40L ~ T-cells en- 
hanced anti-CD3 induced T-cell proliferation and the forma- 
tion of CTL [3]. These data point to a stimulation of the T- 
cells via the CD40L, however, it might be also possible that 
transfected P815 cells are activated alter CD40L binding and 
stimulate the T-cels via an unknown mechanism, e.g. by re- 
lease of some cytokines. 
Third, interaction of the CD40L with the CD40-receptor 
results in downregulation and internalization of the CD40L 
on the surface of T-cells, which may terminate the stimulation 
of the B-cells [4]. The internalization process might be medi- 
ated by a CD40L initiated active signalling mechanism. 
Fourth, patients with X-linked Hyper-lgM syndrome due 
to CD40L mutations are highly susceptible to opportunistic 
infections, e.g. Pneumocystis carinii pneumonia nd crypto- 
sporidial diarrhoe [6]. These infections are T-cell dependent 
and indicate a defect of cellular T-cell function; however, this 
defect could be also explained by the lack of an interaction of 
the defective CD40L with the CD40-receptor on other cells, 
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e.g. monocytes or antigen presenting cells, which might be 
required for efficient stimulation of T-cells. 
A signalling function of the CD40L is further supported by 
the finding that other ligands, in particular the CD30 ligand 
and the OX40-1igand of the TNF-l igand family exhibit similar 
dual functions [23,24]. 
However, application of activating CD40 receptor-antibod- 
ies to CD40L knock-out mice restores cellular and humoral 
immune responses to adenoviral vectors via a B7.2-CD28 de- 
pendent mechanism [25]. Thus, the CD40L may not be abso- 
lutely required for the stimulation of T-cells under these con- 
ditions and the CD40L may function predominantly as a co- 
stimulatory molecule which can be replaced by other strong 
co-stimuli or by upregulation of other stimulatory receptors 
replacing the function of the CD40L in the CD40-receptor 
knock-out mice. 
In summary, we provide evidence for a novel function of 
the CD40L as a receptor molecule. One of the pathways acti- 
vated by the CD40L couples the CD40L directly or indirectly 
to an activation of the neutral sphingomyelinase resulting in 
consumption of cellular sphingomyelin and release of ceram- 
ide. 
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